RSCM
EUCRU

Rock Springs Capital Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Rock Springs Capital Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-206,000
Closed -$2.05M – 153
2021
Q3 		$2.05M Hold
206,000
– – 0.04% 142
2021
Q2 		$2.1M Hold
206,000
– – 0.04% 144
2021
Q1 		$2.06M Hold
206,000
– – 0.05% 141
2020
Q4 		$2.2M Buy
+206,000
New +$2.09M 0.05% 145

Other funds holding EUCRU

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Rock Springs Capital Management's EUCRU Position: Q4 2021 in Review

Rock Springs Capital Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2021, closing a stake of 206,000 shares — an estimated $2.05M sold.

Rock Springs Capital Management first reported a position in EUCRU in Q4 2020 and held it in 4 quarters. The position peaked at $2.2M in Q4 2020. 14 funds tracked by Wall St. Rank hold EUCRU as of Q4 2021.

  • Rock Springs Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2021 after selling out during the quarter.
  • Rock Springs Capital Management sold 206,000 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2021, an estimated $2.05M.
  • Rock Springs Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 4 quarters.
  • Rock Springs Capital Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $2.2M in Q4 2020.
  • 14 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2021.

Based on Rock Springs Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.